Press release
Nontuberculous Mycobacterial Infections Pipeline Outlook 2025 - Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight
Nontuberculous Mycobacterial Infections Pipeline
According to DelveInsight's evaluation, the global Nontuberculous Mycobacterial (NTM) Infections pipeline includes 10+ leading companies actively engaged in advancing more than 10 therapeutic candidates. The analysis highlights ongoing progress in clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and developmental milestones.
Request for sample page @ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
What Are the Key Highlights from the NTM Infections Pipeline Report?
• Several biopharma companies worldwide are consistently working to develop innovative therapies for NTM infections, with notable advancements in recent years.
• Key players in this therapeutic space include Insmed Incorporated, Savara Inc, Paratek Pharmaceuticals Inc, LigaChem Biosciences, Spero Therapeutics, Mannkind Corporation, Pfizer, Agouron Pharmaceuticals, Pharmacia, Janssen Pharmaceutical K.K., and others.
• Prominent emerging therapies include ALIS, Antimycobacterial regimen, Omadacycline Oral Tablet, Delpazolid, SPR720, Clofazimine Inhalation Suspension, Ethambutol hydrochloride, Nelfinavir mesylate, Bedaquiline, and more-expected to significantly influence the NTM Infections market.
• In April 2025, MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for MNKD-101 (Clofazimine Inhalation Suspension), enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial (NTM) lung disease.
• In April 2025, Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a patient that has a condition associated with non-tuberculous mycobacteria (NTM) lung infection.
• In January 2025, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx",688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections. This designation marks a significant milestone for MicuRx in the field of NTM infection treatment.
• November 2024: Paratek Pharmaceuticals announced positive topline Phase IIb data for Nuzyra (omadacycline) in NTM pulmonary disease, showing ≥50% symptom improvement from baseline.
• October 2024: Spero Therapeutics reported interim Phase 2a results of SPR720, demonstrating antimicrobial activity but also raising safety concerns at higher doses, which led to a temporary halt in its development strategy.
What Are Nontuberculous Mycobacterial (NTM) Infections?
NTM Infections are caused by diverse environmental mycobacteria-excluding Mycobacterium tuberculosis and Mycobacterium leprae-commonly found in soil, dust, and water. These infections predominantly affect the lungs but may also involve skin, lymph nodes, and other organs, especially in immunocompromised patients.
While not contagious, NTM Infections are chronic and difficult to treat. Symptoms such as persistent cough, weight loss, fatigue, and breathlessness often mimic tuberculosis or other lung conditions. Diagnosis typically involves sputum cultures, imaging, and molecular testing.
Major causative species include Mycobacterium avium complex (MAC) and Mycobacterium abscessus. Treatment generally requires prolonged multi-drug antibiotic regimens extending over a year, with resistance posing major challenges. Rising prevalence is linked to better diagnostics, increased awareness, and aging populations.
Get a Free Sample PDF Report to know more about Nontuberculous Mycobacterial Infections Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Which Emerging Therapies Are Under Development?
• ALIS - Insmed Incorporated
• Antimycobacterial regimen - Savara Inc
• Omadacycline Oral Tablet - Paratek Pharmaceuticals Inc
• Delpazolid - LigaChem Biosciences, Inc.
• SPR720 - Spero Therapeutics
• Clofazimine Inhalation Suspension - Mannkind Corporation
• Ethambutol hydrochloride - Pfizer, Pharmacia
• Nelfinavir mesylate - Agouron Pharmaceuticals
• Bedaquiline - Janssen Pharmaceutical K.K.
How Are These Therapies Being Administered?
Pipeline therapies are being evaluated across multiple routes of administration (ROA):
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
What Types of Molecules Are in Development?
Therapies fall under various molecular categories, including:
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies
Further Nontuberculous Mycobacterial Infections product details are provided in the report. Download the Nontuberculous Mycobacterial Infections pipeline report to learn more about the emerging Nontuberculous Mycobacterial Infections therapies at:
https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
How Is the Pipeline Being Assessed?
• By product type and stage of development (early, mid, late phase)
• By route of administration
• By molecular type
• Active vs. inactive (discontinued/dormant) projects
• Collaborative and licensing activities
What Factors Are Driving the NTM Infections Market?
• Rising incidence of NTM infections
• Advancements in diagnostic methods
• Increasing awareness and screening initiatives
• Growing elderly and immunocompromised populations
• Expanding pipeline and ongoing R&D investments
What Barriers Are Hindering Market Growth?
• Limited available treatment options
• Long and costly treatment regimens
• Side effects from prolonged antibiotic use
• Resistance to current therapies
• Low commercial interest and regulatory hurdles
Download Sample PDF Report to know more about Nontuberculous Mycobacterial Infections drugs and therapies-
https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
What Is the Scope of the Report?
• Coverage: Global
• Key Nontuberculous Mycobacterial Infections Companies: Insmed Incorporated, Savara Inc, Paratek Pharmaceuticals Inc, LigaChem Biosciences, Inc., Spero Therapeutics, Mannkind Corporation, Pfizer, Agouron Pharmaceuticals, Pharmacia, Janssen Pharmaceutical K.K., and others
• Key Nontuberculous Mycobacterial Infections Therapies: ALIS, Antimycobacterial regimen, Omadacycline Oral Tablet, Delpazolid, SPR720, Clofazimine Inhalation Suspension, Ethambutol hydrochloride, Nelfinavir mesylate, Ethambutol hydrochloride, Bedaquiline, and others
• Nontuberculous Mycobacterial Infections Therapeutic Assessment: Nontuberculous Mycobacterial Infections current marketed and Nontuberculous Mycobacterial Infections emerging therapies
• Nontuberculous Mycobacterial Infections Market Dynamics: Nontuberculous Mycobacterial Infections market drivers and Nontuberculous Mycobacterial Infections market barriers
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nontuberculous Mycobacterial Infections Pipeline Outlook 2025 - Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight here
News-ID: 4152791 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Infections
Campylobacter Infections Market Outlook Report 2032 | Campylobacter Infections M …
DelveInsight's "Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Campylobacter Infections, historical and forecasted epidemiology as well as the Campylobacter Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Campylobacter Infections market report provides current treatment practices, emerging drugs, Campylobacter Infections market share of the individual therapies, and current and forecasted Campylobacter Infections market size…
Point of Care Molecular Diagnostics Market Size Worth $5,665.3 Million By 2028: …
Global “Point of Care Molecular Diagnostics Market” 2021 –2028 Research Report is an extensive Industry report contains an introduction on new trends that can guide the businesses performing in the Life Science industry to recognize the market and make the strategies for their industry growth accordingly. The Point of Care Molecular Diagnostics research report study the market scope, Industry segment, key drivers for development, major segments, and SWOT Analysis.
Global PoC…
Amoxicillin Drugs Market Expansion Projected to Gain an Uptick During 2018 to 20 …
Amoxicillin Drugs: Market Insights
Amoxicillin drugs is a form of generic drugs of Amoxil branded drug commonly used in the treatment of bacterial infections. The Amoxicillin drugs fall under the drug class of β-lactam antibiotic. The increasing number of bacterial infections around the world, especially, in the developing and low-income countries is one of the reasons for the growing demand for Amoxicillin drugs and hence, boosting the growth of Amoxicillin drugs…
Burkholderia Infections Market
Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people,…
Burkholderia Infections Market
Burkholderia infections are caused by Burkholderia cepacia. It is a gram negative bacillus found in aquatic environment. It is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid, irrigation solution etc. B. cepacia can cause health problems to some people such as patients suffering from weakened immune system or chronic lung diseases. Burkholderia infection symptom can vary widely in people,…
Acinetobacter Infections Treatment Market is Propelled by Increasing Incidence R …
Global Acinetobacter Infections Treatment Market: Overview
Acinetobacter baumannii is a rod shaped gram-negative coccobacillus bacterium. This bacterium is becoming an important cause of hospital derived bacterial infection affecting people with weakened immune system. Acinetobacter infections usually affect organ systems, which have a high content of fluid (e.g. peritoneal fluid, respiratory tract, urinary tract, cerebrospinal fluid etc.) leading to infections related to continuous ambulatory peritoneal dialysis and nocosomial pneumonia. At present, acinetobacter…
